From left to right: Dr. Louis Gaboury and Dr. Sylvie Mader, Principal Investigators at IRIC; Dr. André Robidoux, Principal Investigator at the Centre hospitalier de l’Université de Montréal (CHUM) and Research Associate at IRIC.

The Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal and IRICoR, its Centre of Excellence for Commercialization and Research (CECR), welcome the announcement made Friday, February 15 of the creation of the Partnership for Personalized Medicine in Cancer (Partenariat pour la médecine personnalisée en cancer, PMPC).

The Minister of Finance of Québec, Nicolas Marceau, announced that investments of more than 21 million dollars are planned for this project, including 11 million dollars contributed by private partners and 10 million dollars from the Government of Quebec.

The projects supported by this partnership aim to discover, validate and implement in clinical use, new biomarkers that will allow to better diagnose the type of cancer, better monitor its evolution and help guide the optimal treatment for each patient. The purpose of PMPC is also to develop platforms at the forefront of technology in genomics, proteomics, bioinformatics and information technology to integrate within clinical practice the use of these biomarkers and targeted treatments especially for lung, colon and breast cancer.

Two Principal Investigators of IRIC, Dr. Sylvie Mader and Dr. Louis Gaboury and a research associate of the Institute, Dr. André Robidoux of the Centre hospitalier de l’Université de Montréal (CHUM) are collaborators of the PMPC. The IRIC platform of Histology and Molecular Pathology as well as the Genomics and Bioinformatics platforms of the Institute will support this project.

The PMPC will also benefit from the expertise of IRICoR in business development and research commercialization. “This initiative supported by the PMPC is perfectly aligned with the IRIC/IRICoR model based on close cooperation between the actors of the industry, the biomedical research community and universities for novel approaches to treatment of cancer such as personalized medicine” said Dr. Michel Bouvier, CEO of IRICoR, professor in the Department of Biochemistry – Faculty of Medicine at the Université de Montréal and principal investigator at IRIC.

About IRIC

An ultra-modern research hub and training centre located in the heart of Université de Montréal, the Institute for Research in Immunology and Cancer (IRIC) was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this plague. IRIC operates according to a model that is unique inCanada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer. For more information about IRICR, please visit www.iric.ca.

About IRICoR | Institute for Research in Immunology and Cancer – Commercialization of Research

IRICoR is a non-profit organization whose mandate is to accelerate the discovery, development and commercialization of novel drugs that originate from IRIC and Université de Montréal. IRICoR, as aCenterofExcellencein Commercialization and Research, invests in highly innovative projects to rapidly transition them from academia to the market, while identifying the best development partners for these commercially-promising projects. For more information about IRICoR, please visit www.iricor.ca.